FDA approves darolutamide for non-metastatic castration-resistant prostate cancer

(August 1, 2019)

FDA approves darolutamide for non-metastatic castration-resistant prostate cancer On July 30, 2019, the Food and Drug Administration approved darolutamide (NUBEQA, Bayer HealthCare Pharmaceuticals Inc.) for non-metastatic castration-resistant prostate... Continue Reading


New Surgical Technique Shows Potential in Restoring Erectile Function After Radical Prostatectomy

(July 9, 2019)

Cancer Connect News: According to a report from Australian doctors published in the Journal of European Urology minimally invasive end to end nerve grafting can restore erectile function among men who previously underwent radical prostatectomy for prostate... Continue Reading


Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

(June 3, 2019)

After 3 years, 80% of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with testosterone suppression were alive compared to 72% of men who received standard care. Chicago – Enzalutamide, an oral androgen receptor... Continue Reading


Calquence Improves Survival in Relapsed Chronic Lymphocytic Leukemia

(May 20, 2019)

An interim analyses of the phase 3 “ASCEND” clinical trial evaluating single-agent Calquence (acalabrutinib) compared to Rituxan (rituximab) plus idelasib or bendamustine in recurrent chronic lymphocytic leukemia (CLL) is closed early due to favorable... Continue Reading


Zytig Treatment Prolongs Survival in Advanced Prostate Cancer

(May 7, 2019)

Zytig (Abiraterone acetate) plus prednisone and androgen deprivation therapy (ADT) significantly extends overall survival compared with placebo plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (CSPC) About... Continue Reading


Darolutamide Delays Prostate Cancer Progression in Men with Resistant Prostate Cancer

(March 14, 2019)

Results of the phase III ARAMIS clinical trial were published in The New England Journal of Medicine and demonstrated that Darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival compared to placebo plus ADT... Continue Reading


Adjuvant Taxotere Doesn’t Improve Outcomes in Early Stage High Risk Prostate Cancer

(February 11, 2019)

Patients with high-risk, non-metastatic prostate cancer saw no survival advantage and no delay in metastases with the addition of adjuvant docetaxel to androgen deprivation therapy (ADT), according to the results of a pivotal clinical randomized trial... Continue Reading


Targeted Radiation with 177Lu-PSMA-617 is Promising Treatment for Advanced Prostate Cancer

(December 31, 2018)

177Lu-PSMA-617 is a member of a new class of drugs that deliver radiation directly to tumor cells to obliterate them. These targeted radiation treatments consist of a radioactive isotope attached to a molecule that specifically targets tumor cells. In... Continue Reading


FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer

(July 17, 2018)

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population to include patients with both non-metastatic CRPC... Continue Reading


Immediate vs Delayed Androgen Deprivation Therapy in Prostate Cancer

(May 1, 2018)

CancerConnect News: There is an ongoing discussion about the optimal timing of using androgen deprivation therapy (ADT) in men with prostate cancer who have relapsed based on a rising prostate-specific antigen (PSA) and in men with early stage prostate... Continue Reading


Latest Prostate Cancer News By Stage


Early Stage I-II (A-B) Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Early Stage I-II (A-B) Prostate Cancer

Locally Advanced Stage III (C) Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Locally Advanced Stage III (C) Prostate Cancer

Metastatic Stage IV (D) Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Metastatic Stage IV (D) Prostate Cancer

Refactory/Recurrent Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Refactory/Recurrent Prostate Cancer

Screening/Prevention Prostate Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Prostate Cancer